Maggie L. Shaw

Establishing baseline oxygen and cognitive assessments helps community teams safely treat older, higher-risk patients, says Salman Fazal, MD.

Myeloma risk prediction is strong, but matching each patient to optimal therapy is still being tested, says Nikhil C. Munshi, MD.

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Nikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.

Early modeling put sickle cell gene therapy coverage near $0.11 per member per month.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.

Oyepeju Abioye-Akintola, MD, MSc, says unreadable consent forms are a fixable barrier to oncology trial enrollment.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what matters most to AYA patients.

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.

Caution remains necessary when applying ENDURANCE trial findings to high-risk disease, explains Prerna Mewawalla, MD.

Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.

Kittai, of Perlmutter Cancer Center, discusses choosing therapies to fit patients’ lives and how mentoring energizes him.

AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.

Recent ENDURANCE data support 2-year lenalidomide maintenance in standard-risk multiple myeloma and individualize when to stop.

Bhavana Bhatnagar, DO, says payer support for social needs, registries, and survivorship care can help patients access therapy and thrive.

Sagar Lonial, MD, lead investigator of the phase 3 EXCALIBER trial, dissects iberdomide data he presented at IMS 2026 and where mezigdomide fits in.

Fathi, of Mass General Brigham Cancer Institute, says PARADIGM trial data support azacitidine-venetoclax for induction-eligible patients.

Moffitt’s Andrew Kuykenda, MD, lead VERIFY trial investigator, says rusfertide offers durable response and manageable safety.

Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.

Duration of benefit "has to be part of the discussion," emphasizes Rogers of The James/The Ohio State Comprehensive Cancer Center.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

Transplant is no longer the default for young, fit patients with a good donor if they achieve MRD-negative status, says Emily K. Curran, MD

Policy mandates and low-burden trial designs are key to equitable stem cell transplant access, explains Karilyn Larkin, MD.